SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from
the Phase 2b ADVISE trial evaluating
the safety and efficacy of etrasimod, a highly selective,
once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator,
in participants with moderate-to-severe atopic dermatitis (AD),
will be presented at the Revolutionizing Atopic Dermatitis (RAD)
2020 Virtual Conference.
"I am pleased to present the topline results from the ADVISE
Phase 2 trial which support the rationale for etrasimod as a
potential oral, once-daily therapy with a novel mechanism of action
for the treatment of atopic dermatitis. I look forward to seeing
the advancement of etrasimod to the next phase of clinical
development," stated Robert
Bissonnette, MD, FRCPC, Founder and CEO, Innovaderm
Research. "There is a significant unmet clinical need for the
development of novel oral therapeutic options for atopic dermatitis
patients."
Title: Results from ADVISE: a randomized,
double-blind, placebo-controlled Phase 2 study of etrasimod, an
oral, selective, sphingosine 1-phosphate receptor modulator, in
adults with moderate-to-severe atopic
dermatitis
Presenter: Dr. Robert Bissonnette
Authors: Jonathan Silverberg, Robert Bissonnette, Leon
Kircik, Dedee Murrell,
Andrew Selfridge, Gurpreet Ahluwalia, Kris
Liu, Emma Guttman-Yassky
Date/Time: 8:50 – 8:57 AM
ET, Monday, December 14,
2020
Session: Late-Breaking Research Session
About Etrasimod
Etrasimod (APD334) is a next
generation, once-daily, oral, highly selective sphingosine
1-phosphate (S1P) receptor modulator discovered by Arena and
designed for optimized pharmacology and engagement of S1P receptor
1, 4, and 5, which may lead to an improved efficacy and safety
profile.
Etrasimod is intended to provide systemic and local effects on
specific immune cell types and has the potential to treat multiple
immune-mediated inflammatory diseases including ulcerative colitis,
Crohn's disease, eosinophilic esophagitis, atopic dermatitis, and
alopecia areata.
Etrasimod is an investigational compound that is not approved
for any use in any country.
About Arena Pharmaceuticals
ARENA
Pharmaceuticals is a team with a singular purpose – deliver
our important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get our medicines to
patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements may be
identified by words such as "evaluating," "potential," "may,"
"will," and "designed for," and "intended to" and include, without
limitation, statements about the following: the topline results
from the ADVISE Phase 2 clinical trial supporting the rationale for
etrasimod as a potential oral, once-daily therapy with a novel
mechanism of action for the treatment of atopic dermatitis; the
opportunity, development and potential of etrasimod, its
therapeutic potential in immune-mediated inflammatory diseases such
as atopic dermatitis, its ability to satisfy an unmet medical or
clinical need, its potential effects, and its selectivity, safety,
and activity; and Arena's purpose, work, understanding, ideas, and
execution. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the
following: clinical trials and other studies may not proceed at the
time or in the manner expected, or at all; the timing and outcome
of research, development and regulatory review is uncertain, and
Arena's drug candidates may not advance in development or be
approved for marketing; the duration and severity of the COVID-19
pandemic, including but not limited to its impact on Arena's
clinical trials and operations, the operations of Arena's
suppliers, partners, collaborators, licensees, and the capital
markets, which in each case remains uncertain; risks related to
developing and commercializing drugs; Arena may need additional
funds to advance all of its programs; risks and uncertainties
relating to cash and revenues that may be generated from product
sales or other sources, including the impact of competition; risks
related to unexpected or unfavorable new data; nonclinical and
clinical data is voluminous and detailed, and regulatory agencies
may interpret or weigh the importance of data differently and reach
different conclusions than Arena or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
topline data may not accurately reflect the complete results of a
particular study or trial; satisfactory resolution of litigation or
other disagreements with others; government and third-party payor
actions, including relating to reimbursement and pricing; risks
related to relying on licenses or collaborative arrangements,
including lack of control and potential disputes; the entry into or
modification or termination of licenses or collaborative
arrangements; and Arena's and third parties' intellectual property
rights. Additional factors that could cause actual results to
differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with
the Securities and Exchange Commission (SEC), including but not
limited to Arena's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2020, which was
filed with the SEC on November 9,
2020. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contacts:
Patrick
Malloy
Arena Pharmaceuticals, Inc.
Vice President, Investor Relations & Corporate
Communications
pmalloy@arenapharm.com
847.987.4878
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
mknight@arenapharm.com
858.210.3635
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-data-from-the-phase-2b-advise-trial--late-breaker-at-revolutionizing-atopic-dermatitis-conference-301191045.html
SOURCE Arena Pharmaceuticals, Inc.